MP-RM-1
Based on 1 Customer Validation
MP-RM-1 is an antibody-based, non-competitive ErbB-3 inhibitor with a Kd value of 32.7 nM. MP-RM-1 inhibits both ligand-dependent and ligand-independent ErbB-3 activation, blocks ErbB-2/ErbB-3 heterodimerization, induces ErbB-3 internalization and degradation, and suppresses the phosphorylation of downstream Akt. MP-RM-1 exerts its antagonistic effect through a non-competitive mechanism. MP-RM-1 inhibits tumor growth in melanoma and prostate cancer xenograft models in nude mice and reduces the proliferative activity of tumor cells.
For research use only. We do not sell to patients.
- Purity: 96.29%
- Molecular Weight:147.86 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All EGFR Isoforms
More
Biological Activity
Human IgG1 kappa
Human
|
ErbB3 32.7 nM (Kd) |
MP-RM-1 (0.01-10 μg/mL; 15-120 min) inhibits NRG-1β-dependent phosphorylation of ErbB-3 and Akt in a dose- and time-dependent manner in breast cancer cells MDA-MB-435 and melanoma cells IR-8[1].
MP-RM-1 (10 μg/mL) significantly inhibits the colony-forming ability of IR-8 melanoma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MP-RM-1 (20 mg/kg; i.p.; twice weekly) significantly inhibits the growth of DU-145 prostate cancer xenografts in nude mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD-1 nu/nu (7-weeks old, melanoma xenograft via subcutaneous injection of IR-8 cells)[1]
-
Dosage:20 mg/kg (tumor growth delay); 20 mg/kg (tissue analysis)
-
Administration:i.p.; twice weekly (tumor growth delay); i.p.; single injection (tissue analysis)
-
Result:Caused significant tumor growth delay over 8 weeks.
Reduced ErbB-3 expression and Akt phosphorylation significantly compared to controls.
Decreased Ki-67 staining index to 35.8 vs 57.9 in controls (P = 0.048).
Decreased mitotic index to 6.6 vs 9.5 in controls (P = 0.017).
-
Animal Model:CD-1 nu/nu (7-weeks old, prostate cancer xenograft via subcutaneous injection of DU-145 cells)[1]
-
Dosage:20 mg/kg
-
Administration:i.p.; twice weekly
-
Result:Caused significant tumor growth delay over 4 weeks.
Induced statistically significant differences in tumor volume relative to controls at multiple time points.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Immobilized huHER3-Fc can bind MP-RM-1. The EC50 for this effect is 19.07 ng/mL.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 147.86 kDa
-
Color Colorless to off-white
-
SMILES
N/A
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz